Biotechnology

CASI Pharmaceuticals

CASI Pharmaceuticals released FY2025 9 Months Earnings on November 14 (EST), actual revenue USD 13.49 M, actual EPS USD -2.2345

CASI Pharmaceuticals released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 3.075 M (forecast USD 0), actual EPS USD -0.678 (forecast USD -0.4)

CASI Pharmaceuticals released FY2025 Semi-Annual earnings on August 29 (EST), actual revenue USD 10.42 M, actual EPS USD -1.5565

CASI Pharmaceuticals released FY2025 Q2 earnings on August 29 (EST), actual revenue USD 4.175M (forecast USD 6.275M), actual EPS USD -0.8625 (forecast USD -0.47)

CASI Pharmaceuticals Reports Q2 2025 Revenue Growth and Increased Net Loss

CASI Pharmaceuticals' FOLOTYN® Import License in China Has Expired

CASI Pharmaceuticals to Hold Conference Call for Business and Clinical Updates

HC Wainwright Maintains CASI Pharmaceuticals Buy Rating

CASI Pharmaceuticals released FY2025 Q1 earnings on May 16 (EST), actual revenue USD 6.24 M (forecast USD 6.1 M), actual EPS USD -0.6938 (forecast USD -0.61)

CASI Pharma Reports 82% Revenue Growth in Q1 2025 with Losses Expanding

CASI Pharma to Report 61 Cent Loss Per Share in Q1 2025

CASI Pharmaceuticals Acquires Equity Interest in Precision Autoimmune Therapeutics

CASI Pharmaceuticals Receives Updated Non-Binding Acquisition Proposal from Dr. He Weiwu to Acquire Its Entire China Business for $20 Million

CASI Pharmaceuticals released FY2024 annual earnings on March 31 (EST), actual revenue 28.54 M USD (forecast 19.8 M USD), actual EPS -2.5599 USD (forecast -2.56 USD)

CASI Pharmaceuticals released FY2024 Q4 earnings on March 31 (EST), actual revenue 13.36 M USD (forecast 7.394 M USD), actual EPS -0.751 USD (forecast -0.6 USD)

CASI Pharmaceuticals released FY2024 9 Months Earnings on November 15 (EST), with actual revenue of USD 15.18 M and EPS of USD -1.776

CASI Pharmaceuticals released FY2024 Q3 earnings on November 15 (EST), actual revenue 7.793 MUSD (forecast 4.56 MUSD), actual EPS -0.5488 USD (forecast -0.62 USD)

CASI Pharmaceuticals to Release FY2024 Q3 Earnings on November 13, Forecast Revenue 4.56 M USD, EPS -0.62 USD

CASI Pharmaceuticals released FY2024 Semi-Annual earnings on August 16 Pre-Market EST, actual revenue USD 7.388 M, actual EPS USD -1.2261

CASI Pharmaceuticals released FY2024 Q2 earnings on August 16 Pre-Market (EST), actual revenue $3.979M (forecast $4.431M), actual EPS -$0.5151 (forecast -$0.63)

Nuveen Global High Income Fund

WeShop

BLUE ACQUISITION CORP. ORD USD0.0001 CL A (SUBS/RTS) 11/06/2030

Freight Tech

Semrush

PANTAGES CAPITAL ACQUISITION CORP. COM USD0.0001 A (SUBS/RTS) 15/11/2029

Zynex

Safe & Green

Nuvation Bio

Kazia Therapeutics

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

CureVac BV

Rigel Pharma

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap